Pricing Log in Create free account

Neurogene Inc. (NGNE) vs REGENXBIO Inc. (RGNX)

Neurogene Inc. and REGENXBIO Inc. are both Biotechnology companies. Neurogene Inc. and REGENXBIO Inc. are of similar size ($508.5M and $505.9M). Neurogene Inc. has the higher net margin (0.00% vs −113.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Neurogene Inc. leads on 8 and REGENXBIO Inc. on 4.

Valuation

Metric NGNE RGNX Biotechnology median
P/E n/m n/m 10.96
P/S n/m 3.29 9.52
P/B 2.64 3.42 2.23
Price to free cash flow n/m n/m 25.69
EV/EBITDA n/m n/m 0.68
EV/Sales n/m 1.69 9.00
Earnings yield (19.78%) (41.47%) (32.09%)
Free cash flow yield (15.29%) (30.61%) (22.62%)

Profitability

Metric NGNE RGNX Biotechnology median
Gross margin 0.00% 87.54% 68.51%
Operating margin 0.00% (95.68%) 0.00%
Net margin 0.00% (113.85%) 0.00%
Free cash flow margin 0.00% (100.58%) 0.00%
Return on equity (45.32%) (113.24%) (50.12%)
Return on assets (41.02%) (35.36%) (45.12%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NGNE RGNX Biotechnology median
Revenue growth (TTM) — (4.59%) 6.78%
EPS growth (last fiscal year) 0.93% 18.08% 29.88%
Revenue growth, 5-year CAGR — 1.97% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NGNE RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.64 4.74 4.74
Net debt to EBITDA 2.57 1.58 1.01

Dividend

Metric NGNE RGNX Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric NGNE RGNX Biotechnology median
Market cap 505.89m 508.48m 166.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack